The store will not work correctly when cookies are disabled.
We use cookies for optimal website function and to better serve our customers. By continuing to browse you agree to the storing of cookies on your device. See our privacy policy for details.
Allow cookies Deny
CAS NO.: 1171381-49-9; (4-bromo-2-methylphenyl)methanamine hydrochloride. PROPERTIES: This brominated aromatic amine features a bromine atom and a methyl group on a phenyl ring connected to a methanamine group, forming a hydrochloride salt. The (4-bromo-2-methylphenyl)methanamine hydrochloride typically appears as a white to off-white crystalline solid with high aqueous solubility due to its salt form. Its molecular structure includes a bromine atom and a methyl group that influence the electronic properties of the aromatic system. For optimal stability, this compound should be stored at 2-8 degree Celsius in a tightly sealed container under anhydrous conditions. When handling, appropriate safety measures including nitrile gloves and safety goggles are essential. This compound is sensitive to moisture and may hydrolyze in aqueous environments. In case of accidental spillage, clean the area with a damp cloth and dispose of materials according to local regulations. APPLICATIONS: The (4-bromo-2-methylphenyl)methanamine hydrochloride serves as a valuable intermediate in the synthesis of pharmaceuticals, particularly those targeting the central nervous system and cardiovascular conditions. The amine functionality provides a platform for developing receptor modulators with specific binding profiles. In medicinal chemistry, this compound functions as a building block for creating antidepressant and anxiolytic agents where the substituted phenyl group contributes to target engagement. Additionally, the molecule finds utility in chemical biology studies where its defined structure can be used to probe enzyme inhibition mechanisms and cellular signaling pathways. Researchers utilizing this compound benefit from its functional group compatibility, enabling the development of therapeutic agents targeting various disease pathways including neuropsychiatric and cardiovascular conditions.